Description
Nasal Spray Format
This product is a liquid research preparation at a concentration of 1 mg/mL (10 mg total peptide in 10 mL), supplied with a metered nasal‑spray pump for research applications where intranasal administration is the study route. The intranasal route offers partial access to CNS tissue via the olfactory and trigeminal pathways, bypassing first‑pass hepatic metabolism.
Intranasal pharmacology varies substantially by molecule. Small, lipophilic peptides may achieve meaningful CNS concentrations; larger or highly hydrophilic peptides often do not. Peer‑reviewed data for intranasal PK is referenced below where available.
Parent Compound: Selank
Selank is a synthetic heptapeptide (TKPRPGP) analog of tuftsin developed at the Russian Academy of Sciences. It is studied for anxiolytic, antidepressant‑like, and immunomodulatory effects without classical benzodiazepine side effects (no sedation, no dependence signal in published cohorts).
Intranasal Research Context
- Zozulia et al., Zhurnal Nevrologii i Psikhiatrii (2008): intranasal Selank vs. medazepam in generalized anxiety disorder.
- Medvedev et al., Neuroscience and Behavioral Physiology: preclinical anxiolytic profile.
- Russian registration uses intranasal 0.15% solution as the clinical format.
- Western peer‑reviewed evidence is limited.
Preparation Details
- Total peptide: 10 mg Selank
- Volume: 10 mL
- Concentration: 1 mg/mL
- Format: Metered nasal‑spray pump
- Source: Solid‑phase synthesis; ≥98% HPLC, reconstituted in preservative‑containing sterile saline buffer
Known Side Effects — Intranasal Route
- Nasal irritation, rhinorrhea
- Rare mild headache or somnolence
- No benzodiazepine‑like sedation or withdrawal in published cohorts
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
